Nemolizumab May Offer an Alternative Therapeutic Option for Refractory ISM A case report suggests nemolizumab may represent an alternative therapeutic option in refractory ISM when standard treatments fail.

Interleukin-31 (IL-31) pathway inhibition may offer an alternative therapeutic direction for refractory indolent #SystemicMastocytosis (ISM) when standard treatments fail. Case report in @cureusmedical.bsky.social.

Read here: https://bit.ly/3LZSmGT

#RareDisease #ISM #Interleukin31